Inflammatory disease biotech RAPT Therapeutics files for an $86 million IPO

Shutterstock photo

RAPT Therapeutics, a Phase 1 biotech developing therapies for cancer and inflammatory diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

The South San Francisco, CA-based company was founded in 2015 and it plans to list on the Nasdaq under the symbol RAPT. Formerly FLX Bio, RAPT Therapeutics changed its name and filed confidentially on May 24, 2019. BofA Merrill Lynch, Wells Fargo Securities, BMO Capital Markets and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Inflammatory disease biotech RAPT Therapeutics files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?